Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study

Oh, Pok Ja; Lee, Jung Ran; Kim, Sook-Kyoung; Kim, Jeong-Hye

doi:10.1016/j.ejon.2019.101676

Cited by 18 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of the present study indicated that patients who had a higher level of depression and who had more severe CIPN–sensory scores were more likely to have worse overall QoL. These results are consistent with those of previous studies [ 42 ], which reported that CIPN [ 41 ] and depression [ 42 ] lead to restrictions in ADLs [ 42 ] and decreases in mobility and independence [ 43 ] in cancer patients treated with platinum-based antineoplastic agents. Healthcare professionals should evaluate neurological function and provide information on nutritional supplements, aerobic exercise, and balance training that may stimulate peripheral neurological function and enhance daily function, to help patients cope with the adverse effects of chemotherapy [ 44 ].…”

Section: Discussionsupporting

confidence: 91%

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Hung

Liu

Chen

et al. 2021

IJERPH

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL.

show abstract

Section: Discussionsupporting

confidence: 91%

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Hung

Liu

Chen

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…However, at 2year follow-up, the MPN level did decline to the same level as those not treated with chemotherapy. The finding that SPN was mostly impacted by chemotherapy is supported by previous studies [7,11,13]. The question remains whether SPN symptoms will continue to decrease after 2 years, or that it remains a chronic problem after this period of time.…”

Section: Discussionsupporting

confidence: 65%

“…However, most studies, including ours have been cross-sectional. In addition, while several studies among CRC patients have examined the course of CIPN over time, most studies did either not include a CIPN measurement before the start of chemotherapy, did not examine the course longer than 1 year after diagnosis, or did not distinguish between sensory (SPN), motor (MPN), and autonomic (APN) peripheral neuropathy (PN) [11][12][13].…”

mentioning

confidence: 99%

The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients

et al. 2020

View full text Add to dashboard Cite

Purpose To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis. Methods All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis. Results Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level. Conclusions Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient’s lives. Implications for cancer survivors Patients need to be informed of both CIPN and the impact on HRQoL.

show abstract

“…Results of the present study indicated that patients who had a higher level of depression and who had more severe CIPN-sensory scores were more likely to have worse overall QoL. These results are consistent with those of previous studies [37], which reported that CIPN [36] and depression [37] lead to restrictions in ADLs [37] and decreases in mobility and independency [38] in cancer patients treated with platinum-based antineoplastic agents. Healthcare professionals should evaluate neurological function and provide information on nutritional supplements, aerobic exercise, and balance training that may stimulate peripheral neurological function and enhance daily function, to help patients cope with the adverse effects of chemotherapy.…”

Section: Discussionsupporting

confidence: 91%

Impact of Chemotherapy-induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-based Chemotherapy

Hung

Liu

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of cancer treatment that may affect quality of life (QoL). The purposes of this study were to: assess the levels of CIPN, depression, general QoL, and CIPN–related QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy.Methods: This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN, depression, general QoL, and CIPN-related QoL.Results: Of the 93 patients with advanced LC studied, 53.8% and 47.3% reported CIPN–sensory impairment and CIPN–motor impairment, respectively. The most common CIPN symptoms were difficulty getting or maintaining an erection and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL was associated with a higher level of depression, more CIPN-sensory impairment, and a higher cumulative dose of chemotherapy.Conclusion: More than half of LC patients report impairment related to CIPN. This finding highlights the importance of treating these symptoms which significantly impair QoL. A holistic approach — including patient health education, dietary adjustment, nutritional supplements, aerobic exercise, and balance training — is needed to relieve the distressful peripheral neurological symptoms and emotional distress of CIPN during and after treatment for advanced LC.

show abstract

Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study

Cited by 18 publications

References 35 publications

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients

Impact of Chemotherapy-induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-based Chemotherapy

Contact Info

Product

Resources

About